Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial

Jeremy S Abramson, Susan Geyer, Sharmila Giri, Levi Pederson, Ann Hudson, Eric D Hsi, Neha Mehta-Shah, Patrick M Reagan, Richard L Deming, Richard F Little, Steven Gore, Shira N Dinner, Anusha Vallurupalli, Daniel J Landsburg, Brad Kahl, Jonathan W Friedberg, Nancy L Bartlett, John P Leonard

Open source

DOI: 10.1016/s2352-3026(26)00191-2
Published: 2026-09
Container: The Lancet Haematology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-3026-26-00191-2,
  title = {Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial},
  author = {Jeremy S Abramson and Susan Geyer and Sharmila Giri and Levi Pederson and Ann Hudson and Eric D Hsi and Neha Mehta-Shah and Patrick M Reagan and Richard L Deming and Richard F Little and Steven Gore and Shira N Dinner and Anusha Vallurupalli and Daniel J Landsburg and Brad Kahl and Jonathan W Friedberg and Nancy L Bartlett and John P Leonard},
  year = {2026},
  journal = {The Lancet Haematology},
  doi = {10.1016/s2352-3026(26)00191-2},
  url = {https://doi.org/10.1016/s2352-3026(26)00191-2}
}

RIS

TY  - JOUR
TI  - Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial
AU  - Jeremy S Abramson
AU  - Susan Geyer
AU  - Sharmila Giri
AU  - Levi Pederson
AU  - Ann Hudson
AU  - Eric D Hsi
AU  - Neha Mehta-Shah
AU  - Patrick M Reagan
AU  - Richard L Deming
AU  - Richard F Little
AU  - Steven Gore
AU  - Shira N Dinner
AU  - Anusha Vallurupalli
AU  - Daniel J Landsburg
AU  - Brad Kahl
AU  - Jonathan W Friedberg
AU  - Nancy L Bartlett
AU  - John P Leonard
PY  - 2026
JO  - The Lancet Haematology
DO  - 10.1016/s2352-3026(26)00191-2
UR  - https://doi.org/10.1016/s2352-3026(26)00191-2
ER  -

APA

Abramson, J. S., Geyer, S., Giri, S., Pederson, L., Hudson, A., Hsi, E. D., Mehta-Shah, N., Reagan, P. M., Deming, R. L., Little, R. F., Gore, S., Dinner, S. N., Vallurupalli, A., Landsburg, D. J., Kahl, B., Friedberg, J. W., Bartlett, N. L., & Leonard, J. P. (2026). Venetoclax added to dose-adjusted EPOCH-R for newly diagnosed double-hit lymphomas: phase 2 results from ALLIANCE A051701, an open-label, randomised, controlled, phase 2–3 trial. The Lancet Haematology. https://doi.org/10.1016/s2352-3026(26)00191-2

Source records

crossref · retrieved 2026-09-25T22:25:50.474Z